NCT04188405View on ClinicalTrials.gov

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 17, 2020

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
DRUG

Decitabine

Given IV

DRUG

Ponatinib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER